Glomeria Therapeutics, based in Chieti, Italy and led by CEO Andrea Zanella, develops medical devices for the treatment of nephropathy. Its most advanced program targets peritoneal dialysis for patients with chronic renal failure. The company’s therapeutic platform includes biocompatible peritoneal dialysis solutions with low glucose degradation products, a connection device to reduce peritonitis risk (DesmoPD), and an automated peritoneal dialysis device to improve cavity filling management and dialysis efficiency (SmartPD). Glomeria focuses on research, development and commercialization of devices to treat and cure acute forms of nephropathy. The company raised over €1m in venture capital to industrialize its technologies and to finalize clinical studies, leveraging Spindial’s expertise.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2015